double-blind study to compare Fluarix TM with another influenza vaccine. Five open-label, non-randomised studies in high-risk adult populations were performed in selected years from 1995-2000.

Sales of the influenza vaccine, Fluarix, rose 14%. Sales of Established vaccines improved 8%. During the quarter, GSK did not record any sales from the COVID-19 booster vaccine co-developed in ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

The other brands containing thiomersal are Fluarix by GlaxoSmithKline, Influvac by Solvay Health Care and Agrippal by Wyeth. Mercury-free flu jab brands available on the NHS are Begrivac from ...

A second group of adults aged 50 to 64 received mRNA-1083 or GSK’s influenza vaccine Fluarix, once again given alongside Spikevax. mRNA-1083 consists of components of mRNA-1010, Moderna’s ...

In September 2020, the Company launched tetravalent influenza flu vaccine, Fluarix Tetra to help combat influenza.In June, 2021 Company launched the Nucala, first anti-IL5 drug, auto-injector ...

The vaccine segment reported 15 per cent Y-o-Y growth, driven by strong growth for Boostrix, Variritix, and Fluarix. In addition, GSK Pharma is intensifying efforts to increase adult immunisation ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

It has been about a month since the last earnings report for GSK (GSK). Shares have added about 8% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.